Last mentioned: Feb 20, 2026
A critical wave of fourth-quarter 2025 earnings previews highlights a sector-wide focus on clinical execution and commercial scaling for mid-to-large cap biotech players. Summit Therapeutics' ivonescimab progress and BioMarin's Voxzogo expansion remain the primary catalysts for investor sentiment as the industry navigates a disciplined capital environment.
This page surfaces every story mentioning BioMarin Pharmaceutical across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where BioMarin Pharmaceutical was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |